SAGE Therapeutics (SAGE) Announces Positive Secondary Endpoint Data for SAGE-547 Phase 2
Tweet Send to a Friend
Sage Therapeutics (Nasdaq: SAGE) announced positive results on secondary endpoints from its Phase 2 clinical trial of SAGE-547 for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
